Advertisement

Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer

      Abstract

      Neoadjuvant therapy in breast cancer refers to systemic therapy administered prior to definitive surgery. It was originally developed for patients with locally advanced breast cancer (stage III) with the intention of downstaging unresectable tumors, and decreasing the extent of surgical intervention, including axillary lymph node dissection. For patients with inflammatory breast cancer, neoadjuvant therapy is considered a standard of care. Increasingly, the neoadjuvant setting is being utilized to accelerate drug development and approval in triple negative breast cancer, a diverse and aggressive subgroup for which no approved targeted therapies are currently available. This review discusses the use of pathologic complete response as a clinical trial endpoint, the use of imaging and biomarkers to predict response to therapy, and standard of care treatment for triple negative breast cancer. Finally, we review novel targets and drug trials in the neoadjuvant setting.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • King T.A.
        • Morrow M.
        Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.
        Nat Rev Clin Oncol. 2015; 12: 335-343
        • Santa-Maria C.A.
        • Camp M.
        • Cimino-Mathews A.
        • Harvey S.
        • Wright J.
        • Stearns V.
        Neoadjuvant therapy for early-stage breast cancer: current practice, controversies, and future directions.
        Oncology (Williston Park). 2015; 29: 828-838
        • von Minckwitz G.
        • Untch M.
        • Blohmer J.U.
        • et al.
        Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
        J Clin Oncol. 2012; 30: 1796-1804
        • Mauri D.
        • Pavlidis N.
        • Ioannidis J.P.
        Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
        J Natl Cancer Inst. 2005; 97: 188-194
        • Mamounas E.P.
        • Anderson S.J.
        • Dignam J.J.
        • et al.
        Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
        J Clin Oncol. 2012; 30: 3960-3966
        • Gabani P.
        • Merfeld E.
        • Srivastava A.J.
        • et al.
        Predictors of locoregional recurrence after failure to achieve pathologic complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
        J Natl Compr Canc Netw. 2019; 17: 348-356
        • Chen V.E.
        • Gillespie E.F.
        • Zakeri K.
        • et al.
        Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer.
        Adv Radiat Oncol. 2017; 2: 105-109
        • Yau C.
        • van der Noordaa M.
        • Wei J.
        • et al.
        Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: a multi-center pooled analysis.
        2019 (Paper presented at: San Antonio Breast Cancer Symposium, 2019; San Antonio, Texas, December 10-14)
        • Mamounas E.P.
        Neoadjuvant therapy for early-stage breast cancer: a model for individualizing outcomes and tailoring locoregional and systemic therapy.
        Oncology (Williston Park). 2015; 29 (846): 839-840
        • Kalinsky K.
        • Hershman D.L.
        Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting.
        J Comp Eff Res. 2013; 2: 393-403
        • Nekljudova V.
        • Loibl S.
        • von Minckwitz G.
        • et al.
        Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC).
        Contemp Clin Trials. 2018; 71: 194-198
        • Wu K.
        • Yang Q.
        • Liu Y.
        • Wu A.
        • Yang Z.
        Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy.
        World J Surg Oncol. 2014; 12: 95
        • Cortazar P.
        • Zhang L.
        • Untch M.
        • et al.
        Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
        Lancet. 2014; 384: 164-172
      1. United States Food and Drug Administration. Pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval; guidance for industry; availability. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pathologic-complete-response-neoadjuvant-treatment-high-risk-early-stage-breast-cancer-use-endpoint. In. Vol 79. Fed Regist2014:60476-60477. Accessed July 27, 2020.

        • Kuroi K.
        • Toi M.
        • Ohno S.
        • et al.
        Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG.
        Breast Cancer. 2015; 22: 586-595
        • Buzdar A.U.
        • Ibrahim N.K.
        • Francis D.
        • et al.
        Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
        J Clin Oncol. 2005; 23: 3676-3685
        • Bear H.D.
        • Anderson S.
        • Smith R.E.
        • et al.
        Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
        J Clin Oncol. 2006; 24: 2019-2027
        • Korn E.L.
        • Sachs M.C.
        • McShane L.M.
        Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.
        Ann Oncol. 2016; 27: 10-15
        • Kuroi K.
        • Toi M.
        • Ohno S.
        • et al.
        Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG.
        Breast Cancer. 2015; 22: 486-495
        • Berruti A.
        • Amoroso V.
        • Gallo F.
        • et al.
        Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
        J Clin Oncol. 2014; 32: 3883-3891
        • Baselga J.
        • Bradbury I.
        • Eidtmann H.
        • et al.
        • NeoALTTO Study Team
        Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
        Lancet. 2012; 379: 633-640
        • Moreno-Aspitia A.
        • McCormick Holmes E.
        • Jackisch C.
        • et al.
        Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T → L) or their combination (L + T) in the adjuvant treatment of HER2-positive early breast cancer.
        J Clin Oncol. 2017; 35: 502
        • Mieog J.S.
        • van der Hage J.A.
        • van de Velde C.J.
        Neoadjuvant chemotherapy for operable breast cancer.
        Br J Surg. 2007; 94: 1189-1200
        • Spring L.M.
        • Fell G.
        • Arfe A.
        • et al.
        Pathological complete response (pCR) after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival, stratified by breast cancer subtypes and adjuvant chemotherapy usage: patient-level meta-analyses of over 27,000 patients. Proceedings from the 2018 San Antonio Breast Cancer Symposium (SABCS); December 4-8.
        2018 (San Antonio, TX)
        • Rugo H.S.
        • Olopade O.I.
        • DeMichele A.
        • et al.
        • I-SPY 2 Investigators
        Adaptive randomization of veliparib-carboplatin treatment in breast cancer.
        N Engl J Med. 2016; 375: 23-34
        • Yee D.
        • DeMichele A.
        • Isaacs C.
        • et al.
        Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL.
        Cancer Res. 2018; 78: GS3-GS08
        • Masuda N.
        • Lee S.J.
        • Ohtani S.
        • et al.
        Adjuvant capecitabine for breast cancer after preoperative chemotherapy.
        N Engl J Med. 2017; 376: 2147-2159
        • Hurley J.
        • Reis I.M.
        • Rodgers S.E.
        • et al.
        The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.
        Breast Cancer Res Treat. 2013; 138: 783-794
        • Hylton N.M.
        • Gatsonis C.A.
        • Rosen M.A.
        • et al.
        • ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators
        Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival-results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
        Radiology. 2016; 279: 44-55
        • Waldrep A.R.
        • Avery E.J.
        • Rose F.F.
        • et al.
        Breast cancer subtype influences the accuracy of predicting pathologic response by imaging and clinical breast exam after neoadjuvant chemotherapy.
        Anticancer Res. 2016; 36: 5389-5395
        • Connolly R.M.
        • Leal J.P.
        • Goetz M.P.
        • et al.
        TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
        J Nucl Med. 2015; 56: 31-37
        • Masumoto N.
        • Kadoya T.
        • Murakami C.
        • et al.
        Evaluation of contrast-enhanced ultrasonography for early prediction of response to neoadjuvant chemotherapy in triple negative breast cancer.
        Cancer Research. 2017; 77 (abstract P4-02-06)
        • Dieci M.V.
        • Criscitiello C.
        • Goubar A.
        • et al.
        Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
        Ann Oncol. 2015; 26: 1518
        • Denkert C.
        • von Minckwitz G.
        • Brase J.C.
        • et al.
        Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
        J Clin Oncol. 2015; 33: 983-991
        • Mao Y.
        • Qu Q.
        • Zhang Y.
        • Liu J.
        • Chen X.
        • Shen K.
        The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
        PLoS One. 2014; 9: e115103
        • Ibrahim E.M.
        • Al-Foheidi M.E.
        • Al-Mansour M.M.
        • Kazkaz G.A.
        The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
        Breast Cancer Res Treat. 2014; 148: 467-476
        • Couch F.J.
        • Hart S.N.
        • Sharma P.
        • et al.
        Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
        J Clin Oncol. 2015; 33: 304-311
        • Ganesan S.
        • Richardson A.L.
        • Wang Z.C.
        • et al.
        Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer.
        Cold Spring Harb Symp Quant Biol. 2005; 70: 93-97
        • Wang Z.C.
        • Lin M.
        • Wei L.J.
        • et al.
        Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers.
        Cancer Res. 2004; 64: 64-71
        • Richardson A.L.
        • Wang Z.C.
        • De Nicolo A.
        • et al.
        X chromosomal abnormalities in basal-like human breast cancer.
        Cancer Cell. 2006; 9: 121-132
        • Turner N.
        • Tutt A.
        • Ashworth A.
        Hallmarks of ‘BRCAness’ in sporadic cancers.
        Nat Rev Cancer. 2004; 4: 814-819
        • Lord C.J.
        • Ashworth A.
        BRCAness revisited.
        Nat Rev Cancer. 2016; 16: 110-120
        • Spugnesi L.
        • Gabriele M.
        • Scarpitta R.
        • et al.
        Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
        Genes Chromosomes Cancer. 2016; 55: 915-924
        • Tanino H.
        • Kosaka Y.
        • Nishimiya H.
        • et al.
        BRCAness and prognosis in triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
        PLoS One. 2016; 11: e0165721
        • Mayer E.L.
        • Gupta Abramson V.
        • Jankowitz R.C.
        • et al.
        TBCRC 030: a randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—evaluating the homologous recombination deficiency (HRD) biomarker.
        J Clin Oncol. 2019; 37: 507
        • Liedtke C.
        • Gluz O.
        • Nitz U.
        • et al.
        Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. Paper presented at: Oncology Research and Treatment, 2016; August 4-6.
        2016 (Toronto, Ontario, Canada)
        • Sharma P.
        • López-Tarruella S.
        • García-Saenz J.A.
        • et al.
        Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts.
        Clin Cancer Res. 2017; 23: 649-657
        • Sharma P.
        • López-Tarruella S.
        • García-Saenz J.A.
        • et al.
        Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel.
        Clin Cancer Res. 2018; 24: 5820-5829
        • Campbell J.I.
        • Yau C.
        • Krass P.
        • et al.
        Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
        Breast Cancer Res Treat. 2017; 165: 181-191
        • von Minckwitz G.
        • Schneeweiss A.
        • Loibl S.
        • et al.
        Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
        Lancet Oncol. 2014; 15: 747-756
        • McAndrew N.
        • DeMichele A.
        Neoadjuvant chemotherapy considerations in triple-negative breast cancer.
        J Target Ther Cancer. 2018; 7: 52-69
        • Wang L.Y.
        • Xie H.
        • Zhou H.
        • Yao W.X.
        • Zhao X.
        • Wang Y.
        Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials.
        Saudi Med J. 2017; 38: 18-23
        • Sikov W.M.
        • Berry D.A.
        • Perou C.M.
        • et al.
        Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
        J Clin Oncol. 2015; 33: 13-21
        • Bell R.
        • Brown J.
        • Parmar M.
        • et al.
        Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
        Ann Oncol. 2017; 28: 754-760
        • Gerber B.
        • Loibl S.
        • Eidtmann H.
        • et al.
        • German Breast Group Investigators
        Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
        Ann Oncol. 2013; 24: 2978-2984
        • Nahleh Z.
        • Botrus G.
        • Dwivedi A.
        • Jennings M.
        • Nagy S.
        • Tfayli A.
        Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: a meta-analysis of randomized controlled trials.
        Mol Clin Oncol. 2019; 10: 357-365
        • Montero A.J.
        • Escobar M.
        • Lopes G.
        • Glück S.
        • Vogel C.
        Bevacizumab in the treatment of metastatic breast cancer: friend or foe?.
        Curr Oncol Rep. 2012; 14: 1-11
        • Gianni L.
        • Huang C.-H.
        • Egle D.
        • et al.
        NeoTRIPaPDL1 Michelangelo randomized study. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer.
        Cancer Res. 2020; 80 (GS3-04)
        • Schmid P.
        • Park Y.H.
        • Ferreira M.
        • et al.
        GS3-03. KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer: pathologic complete response in key subgroups and by treatment exposure, residual cancer burden, and breast-conserving surgery.
        2019 (Presented at San Antonio Breast Cancer Symposium; San Antonio, TX: December 10-14)
        • Litton J.K.
        • Rugo H.S.
        • Ettl J.
        • et al.
        Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
        N Engl J Med. 2018; 379: 753-763
        • Loibl S.
        • O’Shaughnessy J.
        • Untch M.
        • et al.
        Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
        Lancet Oncol. 2018; 19: 497-509
        • Abraham J.
        • Vallier A.
        • Qian W.
        • et al.
        Abstract OT2-01-15: PARTNER-Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.
        2016 (Presented at San Antonio Breast Cancer Symposium; San Antonio, TX: December 6-10)
        • Fasching P.A.
        • Jackisch C.
        • Rhiem K.
        • et al.
        GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).
        J Clin Oncol. 2019; 37: 506
        • Gradishar W.J.
        • Krasnojon D.
        • Cheporov S.
        • et al.
        Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
        J Clin Oncol. 2009; 27: 3611-3619
        • Untch M.
        • Jackisch C.
        • Schneeweiss A.
        • et al.
        German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
        Lancet Oncol. 2016; 17: 345-356
        • Barker A.D.
        • Sigman C.C.
        • Kelloff G.J.
        • Hylton N.M.
        • Berry D.A.
        • Esserman L.J.
        I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
        Clin Pharmacol Ther. 2009; 86: 97-100
        • Huggins-Puhalla S.L.
        • Han H.S.
        • Diéras V.
        • et al.
        Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).
        J Clin Oncol. 2015; 33: 155
        • Nanda R.
        • Liu M.C.
        • Yau C.
        • et al.
        Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2.
        J Clin Oncol. 2017; 35: 506